PSMA-PET has already changed how physicians stage prostate cancer, detect recurrence and select patients for targeted radioligand therapy. Telix Pharmaceuticals is now trying to move the technology considerably earlier in the patient journey, potentially before physicians even know whether a patient has prostate cancer.
The company has completed enrollment in its Phase III BiPASS study evaluating Illuccix and Gozellix Ga-68 PSMA-11 imaging in combination with MRI in the pre-biopsy setting. A total of 350 patients have been enrolled across sites in the United States and Australia, with the study designed to determine whether adding PSMA-PET to MRI can improve diagnostic accuracy, better target biopsies and reduce procedures that ultimately prove unnecessary.
If the strategy works, Telix won't simply have another PSMA imaging indication. It could help establish an entirely new point in the prostate cancer diagnostic pathway where molecular imaging becomes part of deciding whether an invasive diagnostic procedure should happen at all.
Most PSMA imaging today occurs after prostate cancer has already entered the clinical picture. Physicians use it to stage newly diagnosed disease, locate recurrent cancer and increasingly determine whether patients are candidates for PSMA-targeted radioligand therapy. BiPASS changes that sequence by asking whether PSMA-PET can provide enough additional information before biopsy to influence who actually needs the procedure.
That distinction dramatically expands the potential patient population. Telix says more than three million prostate biopsies are performed globally every year and cites research indicating that a substantial proportion ultimately produce negative results. The company has also pointed to earlier research suggesting that combining PSMA-PET with MRI could meaningfully reduce unnecessary biopsies while improving the identification of clinically significant disease.
Even modest penetration into a population measured in millions of annual procedures would create a very different commercial opportunity from traditional PSMA imaging indications. Instead of relying primarily on patients with established prostate cancer, molecular imaging could begin capturing patients during the diagnostic workup itself.
The strategy fits an increasingly important theme in molecular imaging: a diagnostic scan doesn't necessarily have to replace another imaging test to create economic value. Sometimes the more compelling proposition is preventing a more expensive or invasive procedure from happening unnecessarily.
Prostate biopsy consumes clinical resources and carries risks including bleeding, infection and urinary complications. It can also create significant anxiety for patients, particularly when the procedure ultimately determines that clinically significant cancer is not present. If PSMA-PET combined with MRI can reliably identify patients unlikely to benefit from biopsy while improving targeting in patients who do require one, the economics of molecular imaging begin to look different.
The cost of the scan would then be weighed against the procedures it potentially avoids, complications that don't occur and clinical resources that can be directed elsewhere. That doesn't automatically guarantee favorable reimbursement, but it creates a much stronger health-economic argument than simply adding another imaging procedure to an already expensive diagnostic pathway.
Telix also disclosed that it has positively engaged with the FDA on a New Drug Application pathway in the United States that, if successful, could support reimbursement as a new product and broaden access to Ga-68 PSMA-PET across a significantly larger patient population.
That detail deserves attention because reimbursement is often where promising diagnostic concepts encounter commercial reality. Demonstrating that an imaging agent improves clinical decision-making is only part of building a successful radiopharmaceutical product. Developers also have to establish who pays for the scan, how much they pay and whether reimbursement provides hospitals and imaging centers with enough economic incentive to offer it.
Telix appears to be thinking about those questions while BiPASS remains in clinical development rather than waiting until after a regulatory decision. That approach reflects a broader maturation of radiopharmaceutical commercialization, where regulatory strategy, reimbursement, manufacturing and market access increasingly have to develop alongside the clinical program.
There is a larger industry implication behind BiPASS. The commercial ceiling for molecular imaging increases considerably when PET begins influencing decisions earlier in the patient journey rather than being deployed primarily after conventional diagnostics have already established disease.
That evolution is already occurring elsewhere in nuclear medicine. PET increasingly helps determine eligibility for targeted therapies, characterize disease biology and influence treatment selection. Pre-biopsy PSMA imaging would push the concept another step upstream by allowing molecular imaging to influence whether the procedure traditionally used to establish the diagnosis should happen in the first place.
If BiPASS succeeds, the question for physicians may no longer be simply whether PSMA-PET should be used after a prostate cancer diagnosis. It could become whether certain patients should undergo PSMA-PET before physicians decide to perform the biopsy that establishes that diagnosis.
For Telix, that could translate into a substantially larger addressable market. For nuclear medicine, the significance may be even greater: another step toward molecular imaging becoming a front-line clinical decision-making technology rather than a tool reserved for later stages of the cancer journey.
